Senolytic GPX4 Inhibitor Compounds With Improved Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current senolytic compounds, such as Bcl2 family inhibitors, have limitations in solubility and oral bioavailability, and there is a need for more effective compounds that can selectively target and eliminate senescent cells to treat age-related diseases and disorders associated with GPX4 activity.
Innovation Solution
Development of novel compounds, including those of Formula (I) and (II), which inhibit GPX4 and induce ferroptosis in senescent cells, providing senolytic properties to address the accumulation of senescent cells and associated pathologies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current senolytic compounds (e.g., Bcl2 family inhibitors) are used to eliminate senescent cells, then senescent cell clearance is achieved, but solubility and oral bioavailability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of Bcl2 family inhibitor compounds by introducing specific substituents and functional groups (e.g., Formula I and Formula II structures with varied R groups) to improve solubility and oral bioavailability while preserving the core mechanism of action against senescent cells
Solution Approach 2:
The invention develops composite chemical structures that combine the pharmacophore of Bcl2 inhibitors with additional functional moieties that enhance solubility properties, creating new hybrid compounds that address both efficacy and delivery limitations
2Reliability
If GPX4 inhibition is used to induce ferroptosis in senescent cells, then selective elimination of senescent cells is achieved, but off-target effects on GPX4-dependent pathways may occur
Solution Approach 1:
The patent exploits the unique vulnerability of senescent cells to GPX4 inhibition by leveraging their specific dependence on this pathway for survival, while normal cells maintain sufficient GPX4 activity to resist the same level of inhibition, thus achieving selective toxicity
Solution Approach 2:
The compounds are designed to achieve partial GPX4 inhibition sufficient to induce ferroptosis in senescent cells, which have reduced GPX4 activity and increased oxidative stress, while avoiding complete inhibition that would cause off-target effects in healthy cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively target and eliminate senescent cells, reducing oxidative stress and associated diseases, with potential applications in treating a wide range of age-related pathologies, including cancer, fibrosis, and neurodegenerative disorders.
Implementation Method 1
compounds which inhibit GPX4... inhibit GPX4 and induce ferroptosis in senescent cells
Implementation Method 2
reducing oxidative stress and associated diseases
Data Source
AI summary
The present invention relates to compounds that kill senescent cells i.e., senolytic compounds and compounds which inhibit GPX4. The present invention also provides compounds and methods for treating senescence-associated diseases or disorders, and compounds and methods for treating diseases or disorders impacted by GPX4.